FibroTest-ActiTest as a non-invasive marker of liver fibrosis

Gastroenterologie Clinique et Biologique

Volumn 32, Issue 6 SUPPL. 1, 2008, Pages 22-39

  Halfon, Philippe ^a   Munteanu, Mona ^b   Poynard, Thierry ^c  

^a Hospital Ambroise Pare   (France)

^b BioPredictive Paris ^*  (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

ALD; CHB; Fibrotest Actitest; Hepatite C; NAFld; Non invasive marker of liver fibrosis

Indexed keywords

BIOLOGICAL MARKER;

ADULT; ALCOHOL LIVER DISEASE; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FATTY LIVER; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; SENSITIVITY ANALYSIS;

BIOLOGICAL MARKERS; HEMATOLOGIC TESTS; HUMANS; LIVER CIRRHOSIS;

EID: 54349089348     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0399-8320(08)73991-5     Document Type: Article

References (61)

1. Imbert-Bismut F., Ratziu V., Pieroni L., Charlotte F., Benhamou Y., and Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 357 (2001) 1069-1075
2. Gebo K.A., Herlong H.F., Torbenson M.S., Jenckes M.W., Chander G., Ghanem K.G., et al. Role of liver biopsy in management of chronic hepatitis C: a systematic review. Hepatology 36 (2002) S161-S172
3. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 20 (1994) 15-20
4. Poynard T., Imbert-Bismut F., Munteanu M., and Ratziu V. FibroTest-FibroSURE: towards a universal biomarker of liver fibrosis? Expert Rev Mol Diagn 5 (2005) 15-21
5. Poynard T., Imbert-Bismut F., Munteanu M., Messous D., Myers R.P., Thabut D., et al. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol 3 (2004) 8
6. Myers R.P., Tainturier M.H., Ratziu V., Piton A., Thibault V., Imbert-Bismut F., et al. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol 39 (2003) 222-230
7. Poynard T., Zoulim F., Ratziu V., Degos F., Imbert-Bismut F., Deny P., et al. Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection. Am J Gastroenterol 100 (2005) 1970-1980
8. Naveau S., Raynard B., Ratziu V., Abella A., Imbert-Bismut F., Messous D., et al. Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease. Clin Gastroenterol Hepatol 3 (2005) 167-174
9. Ratziu V., Massard J., Charlotte F., Messous D., Imbert-Bismut F., Bonyhay L., et al. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 6 (2006) 6
10. Naveau S, Gaudé G, Asnacios A, Agostini H, Abella A, Barri-Ova N, et al. Diagnostic and prognostic values of non-invasive biomarkers of fibrosis in patients with alcoholic liver disease. Hepatology 2008; (in press).
11. Poynard T., Morra R., Ingiliz P., Imbert-Bismut F., thabut D., Messous D., et al. Biomarkers of liver fibrosis. Adv Clin Chem 46 (2008) 131-152
12. Poynard T, Munteanu M, Morra R, Ngo Y, Imbert-Bismut F, thabut D, et al. Methodological aspects for the interpretation of liver fibrosis non-invasive biomarkers: a 2008 update. Gastroenterol Clin Biol 2008; (in press).
13. Munteanu M., Imbert-Bismut F., Messous D., Morra R., Thabut D., Lebray P., et al. Reproducibility of non-invasive fibrosis biomarkers, FibroMeter and FibroTest, could be improved by respecting the analytical standardizations. Clin Biochem 41 (2008) 1113-1114
14. Imbert-Bismut F., Messous D., Raoult A., Poynard T., Bertrand J.J., Marie P.A., et al. Results transferability on RXL, ARX, X-Pand BN2 (Dade Behring) and modular DP (Roche Diagnostics) analysers: application to component assays of fibrotest and Actitest. Ann Biol Clin (Paris) 63 (2005) 305-313
15. Bossuyt P.M., Reitsma J.B., Bruns D.E., Gatsonis C.A., Glasziou P.P., Irwig L.M., et al., The Standards for Reporting of Diagnostic Accuracy Group. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Croat Med J 44 (2003) 635-638
16. Easterbrook P.J., Berlin J.A., Gopalan R., and Matthews D.R. Publication bias in clinical research. Lancet 337 (1991) 867-872
17. Rossi E., Adams L., Prins A., Bulsara M., de Boer B., Garas G., et al. Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients. Clin Chem 49 (2003) 450-454
18. Myers R.P., Benhamou Y., Imbert-Bismut F., Thibault V., Bochet M., Charlotte F., et al. Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients. Aids 17 (2003) 721-725
19. Castera L., Vergniol J., Foucher J., Le Bail B., Chanteloup E., Haaser M., et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 128 (2005) 343-350
20. Colletta C., Smirne C., Fabris C., Toniutto P., Rapetti R., Minisini R., et al. Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases. Hepatology 42 (2005) 838-845
21. Varaut A., Fontaine H., Serpaggi J., Verkarre V., Vallet-Pichard A., Nalpas B., et al. Diagnostic accuracy of the fibrotest in hemo-dialysis and renal transplant patients with chronic hepatitis C virus. Transplantation 80 (2005) 1550-1555
22. Sebastiani G., Vario A., Guido M., Noventa F., Plebani M., Pistis R., et al. Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C. J Hepatol 44 (2006) 686-693
23. Wilson L.E., Torbenson M., Astemborski J., Faruki H., Spoler C., Rai R., et al. Progression of liver fibrosis among injection drug users with chronic hepatitis C. Hepatology 43 (2006) 788-795
24. Zhao L., Xu D., Lu Z., Zhao H., Lang Z., and Wang C. Validation of Fibrotest to diagnose liver fibrosis to patients with chronic hepatitis B. Chinese Journal of Practical Internal Medicine 27 (2007) 1274-1277
25. Thabut D., Naveau S., Charlotte F., Massard J., Ratziu V., Imbert-Bismut F., et al. The diagnostic value of biomarkers (AshTest) for the prediction of alcoholic steato-hepatitis in patients with chronic alcoholic liver disease. J Hepatol 44 (2006) 1175-1185
26. Cales P., Oberti F., Michalak S., Hubert-Fouchard I., Rousselet M.C., Konate A., et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 42 (2005) 1373-1381
27. Halfon P., Bacq Y., De Muret A., Penaranda G., Bourliere M., Ouzan D., et al. Comparison of test performance profile for blood tests of liver fibrosis in chronic hepatitis C. J Hepatol 46 (2007) 395-402
28. Leroy V., Hilleret M.N., Sturm N., Trocme C., Renversez J.C., Faure P., et al. Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C. J Hepatol 46 (2007) 775-782
29. Grigorescu M., Rusu M., Neculoiu D., Radu C., Serban A., Catanas M., et al. The FibroTest value in discriminating between insignificant and significant fibrosis in chronic hepatitis C patients. The Romanian experience. J Gastrointestin Liver Dis 16 (2007) 31-33
30. Vallet-Pichard A., Mallet V., Nalpas B., Verkarre V., Nalpas A., Dhalluin-Venier V., et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and Fibrotest. Hepatology 46 (2007) 32-36
31. Morali G., Maor Y., Klar R., Braun M., Ben Ari Z., Bujanover Y., et al. Fibrotest-Actitest: the biochemical marker of liver fibrosis - The Israeli Experience. Israeli Med Assoc J 9 (2007) 588-591
32. Sebastiani G., Vario A., Guido M., and Alberti A. Sequential algorithms combining non-invasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B. World J Gastroenterol 13 (2007) 525-531
33. Adler M., Gulbis B., Moreno C., Evrard S., Verset G., Golstein P., et al. The predictive value of FIB-4 versus FibroTest, APRI. FibroIndex and Forns index to noninvasively estimate fibrosis in hepatitis C and nonhepatitis C liver diseases. Hepatology 47 (2008) 762-763
34. Callewaert N., Van Vlierberghe H., Van Hecke A., Laroy W., Delanghe J., and Contreras R. Noninvasive diagnosis of liver cirrhosis using DNAsequencer-based total serum protein glycomics. Nat Med 10 (2004) 429-434
35. Coco B., Oliveri F., Maina A.M., Ciccorossi P., Sacco R., and Colombatto P. Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases. J Viral Hepat 14 (2007) 360-369
36. Poynard T., Imbert-Bismut F., Ratziu V., Chevret S., Jardel C., Moussalli J., et al. Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial. J Viral Hepat 9 (2002) 128-133
37. Poynard T., McHutchison J., Manns M., Myers R.P., and Albrecht J. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin. Hepatology 38 (2003) 481-492
38. Halfon P., Imbert-Bismut F., Messous D., Antoniotti G., Benchetrit D., Cart-Lamy P., et al. A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease. Comp Hepatol 1 (2002) 3
39. Sène D., Limal N., Messous D., Ghillani-Dalbin P., Charlotte F., Thiollière J.M., et al. Biological markers of liver fibrosis and activity as non-invasive alternatives to liver biopsy in patients with chronic hepatitis C and associated mixed cryoglobuline-mia vasculitis. Clin Biochem 39 (2006) 715-721
40. Bedossa P., Poynard T., and The METAVIR Cooperative Study Group. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 24 (1996) 289-293
41. Bedossa P., Dargere D., and Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 38 (2003) 1449-1457
42. DeLong E.R., DeLong D.M., and Clarke-Pearson D.L. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44 (1988) 837-845
43. Zhou X., Obuchowski N., and McClish D. Statistical Methods in Diagnostic Medicine (2002), John Wiley & Sons
44. Poynard T., Halfon P., Castera L., Charlotte F., Le Bail B., Munteanu M., et al. Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation. Aliment Pharmacol Ther 25 (2007) 733-739
45. Poynard T., Halfon P., Castera L., Munteanu M., Imbert-Bismut F., Ratziu V., et al. Standardization of ROC Curve Areas for Diagnostic Evaluation of Liver Fibrosis Markers Based on Prevalences of Fibrosis Stages. Clin Chem 53 (2007) 1615-1622
46. Ngo Y., Munteanu M., Messous D., Charlotte F., Imbert-Bismut F., Thabut D., et al. A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Clin Chem 52 (2006) 1887-1896
47. Ngo Y., Benhamou Y., Thibault V., Ingiliz P., Munteanu M., Lebray P., et al. An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest-ActiTest) and viral load. PLoS ONE 3 (2008) e2573
48. Cacoub P., Carrat F., Bedossa P., Lambert J., Penaranda G., Perronne C., et al. Comparison of non-invasive liver fibrosis biomarkers in HIV/HCV co-infected patients: The fibrovic study - ANRS HC02. J Hepatol 48 (2008) 765-773
49. Maor Y., Cales P., Bashari D., Kenet G., Lubetsky A., Luboshitz J., et al. Improving estimation of liver fibrosis using combination and newer noninvasive biomarker scoring systems in hepatitis C-infected haemophilia patients. Haemophilia 13 (2007) 722-729
50. Sene D., Limal N., Messous D., Ghillani-Dalbin P., Charlotte F., Thiolliere J.M., et al. Biological markers of liver fibrosis and activity as non-invasive alternatives to liver biopsy in patients with chronic hepatitis C and associated mixed cryoglobuline-mia vasculitis. Clin Biochem 39 (2006) 715-721
51. Ritchie R.F., Palomaki G.E., Neveux L.M., Navolotskaia O., Ledue T.B., and Craig W.Y. Reference distributions for alpha2-macroglobulin: a practical, simple and clinically relevant approach in a large cohort. J Clin Lab Anal 18 (2004) 139-147
52. Castera L., Foucher J., Bertet J., Couzigou P., and de Ledinghen V. FibroScan and FibroTest to assess liver fibrosis in HCV with normal aminotransferases. Hepatology 43 (2006) 373-374
53. Poynard T., Munteanu M., Ngo Y., Torres M., Benhamou Y., Thabut D., et al. Diagnostic value of FibroTest with normal serum aminotransferases. Hepatology 43 (2006) 374-375
54. Poynard T., Munteanu M., Ngo Y., Moussalli J., Lebray P., Thabut D., et al. FibroTest is effective in patients with normal transaminases, when accuracy is standardized on fibrosis stage prevalence. J Viral Hepat 15 (2008) 472-473
55. Jacqueminet S., Lebray P., Morra R., Munteanu M., Devers L., Messous D., et al. Screening for liver fibrosis by using a noninvasive biomarker in patients with diabetes. Clin Gastroenterol Hepatol 6 (2008) 828-831
56. Hamelet E., Munteanu M., Thibault V., Imbert-Bismut F., Morra R., Charlotte F., et al. Interest of fibrotest-actitest (FT-AT) in the Follow-up of liver transplanted (LT) patients: a pilot study (abstract). J Hepatol 48 (2008) S92-S93
57. Thabut D., Le Calvez S., Thibault V., Massard J., Munteanu M., Di Martino V., et al. Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease?. Am J Gastroenterol 101 (2006) 1260-1267
58. de Lédinghen V., Le Bail B., Rebouissoux L., Fournier C., Foucher J., Miette V., et al. Liver stiffness measurement in children using FibroScan: feasibility study and comparison with Fibrotest, aspartate transaminase to platelets ratio index, and liver biopsy. J Pediatr Gastroenterol Nutr 45 (2007) 443-450
59. Poynard T., Ratziu V., Benhamou Y., Thabut D., and Moussalli J. Biomarkers as a first-line estimate of injury in chronic liver diseases: time for a moratorium on liver biopsy?. Gastroenterology 128 (2005) 1146-1148
60. Castera L., Denis J., Babany G., and Roudot-Thoraval F. Evolving practices of non-invasive markers of liver fibrosis in patients with chronic hepatitis C in France: time for new guidelines?. J Hepatol 46 (2007) 528-529
61. Fontaine H., Petitprez K., Roudot-Thoraval F., and Trinchet J.C. Guidelines for the diagnosis of uncomplicated cirrhosis. Gastroenterol Clin Biol 31 (2007) 504-509